EKEugene Krustev

Eugene Krustev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eugene Krustev has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus

    by Eugene Krustev, John G Hanly, Ricky Chin, Katherine A Buhler, Murray B Urowitz, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sánchez-Guerrero, Sasha Bernatsky, et al.

    Background Cranial neuropathies (CN) are a rare neuropsychiatric SLE (NPSLE) manifestation. Previous studies reported that antibodies to the kinesin family member 20B (KIF20B) (anti-KIF20B) protein were associated with idiopathic ataxia and CN. We assessed anti-KIF20B as a potential biomarker for NPSLE in an international SLE inception cohort. Methods Individuals fulfilling the revised 1997 American College of Rheumatology (ACR) SLE classification criteria were enrolled from 31 centres from 1999 to 2011 and followed annually in the Systemic Lupus Erythematosus International Collaborating Clinics inception cohort. Anti-KIF20B testing was performed on baseline (within 15 months of diagnosis or first annual visit) samples using an addressable laser bead immunoassay. Logistic regression (penalised maximum likelihood and adjusting for confounding variables) examined the association between anti-KIF20B and NPSLE manifestations (1999 ACR case definitions), including CN, occurring over the first 5 years of follow-up. Results Of the 1827 enrolled cohort members, baseline serum and 5 years of follow-up data were available on 795 patients who were included in this study: 29.8% were anti-KIF20B-positive, 88.7% female, and 52.1% White. The frequency of anti-KIF20B positivity differed only for those with CN (n=10) versus without CN (n=785) (70.0% vs 29.3%; OR 5.2, 95% CI 1.4, 18.5). Compared with patients without CN, patients with CN were more likely to fulfil the ACR haematological (90.0% vs 66.1%; difference 23.9%, 95% CI 5.0%, 42.8%) and ANA (100% vs 95.7%; difference 4.3%, 95% CI 2.9%, 5.8%) criteria. In the multivariate analysis adjusting for age at baseline, female, White race and ethnicity, and ACR haematological and ANA criteria, anti-KIF20B positivity remained associated with CN (OR 5.2, 95% CI 1.4, 19.1). Conclusion Anti-KIF20B is a potential biomarker for SLE-related CN. Further studies are needed to examine how autoantibodies against KIF20B, which is variably expressed in a variety of neurological cells, contribute to disease pathogenesis.


  • Open Access

    Alpha‐1‐antitrypsin reduces inflammation and exerts chondroprotection in arthritis

    by Magdalena K. Kaneva, Milind M. Muley, Eugene Krustev, Allison R. Reid, Patricia R. Souza, Francesco Dell’aCcio, Jason J. McDougall, Mauro Perretti

    While new treatments have been developed to control joint disease in rheumatoid arthritis, they are partially effective and do not promote structural repair of cartilage. Following an initial identification of α‐1‐Antitrypsin (AAT) during the resolution phase of acute inflammation, we report here the properties of this protein in the context of cartilage protection, joint inflammation, and associated pain behavior. Intra‐articular and systemic administration of AAT reversed joint inflammation, nociception, and cartilage degradation in the KBxN serum and neutrophil elastase models of arthritis. Ex vivo analyses of arthritic joints revealed that AAT promoted transcription of col2a1, acan, and sox9 and downregulated mmp13 and adamts5 gene expression. In vitro studies using human chondrocytes revealed that SERPINA1 transfection and rAAT protein promoted chondrogenic differentiation through activation of PKA‐dependent CREB signaling and inhibition of Wnt/β‐catenin pathways. Thus, AAT is endowed with anti‐inflammatory, analgesic, and chondroprotective properties that are partially inter‐related. We propose that AAT could be developed for new therapeutic strategies to reduce arthritic pain and repair damaged cartilage.


  • Open Access

    Prophylactic inhibition of neutrophil elastase prevents the development of chronic neuropathic pain in osteoarthritic mice

    by Milind M. Muley, Eugene Krustev, Allison R. Reid, Jason J. McDougall

    A subset of osteoarthritis (OA) patients experience joint pain with neuropathic characteristics. Mediators such as neutrophil elastase, a serine proteinase, may be released during acute OA inflammatory flares. We have previously shown that local administration of neutrophil elastase causes joint inflammation and pain via activation of proteinase-activated receptor-2 (PAR2). The aim of this study was to examine the contribution of endogenous neutrophil elastase and PAR2 to the development of joint inflammation, pain, and neuropathy associated with monoiodoacetate (MIA)-induced experimental OA. MIA (0.3 mg/10 μl) was injected into the right knee joint of male C57BL/6 mice (20–34 g). Joint inflammation (edema, leukocyte kinetics), neutrophil elastase proteolytic activity, tactile allodynia, and saphenous nerve demyelination were assessed over 14 days post-injection. The effects of inhibiting neutrophil elastase during the early inflammatory phase of MIA (days 0 to 3) were determined using sivelestat (50 mg/kg i.p.) and serpinA1 (10 μg i.p.). Involvement of PAR2 in the development of MIA-induced joint inflammation and pain was studied using the PAR2 antagonist GB83 (5 μg i.p. days 0 to 1) and PAR2 knockout animals. MIA caused an increase in neutrophil elastase proteolytic activity on day 1 (P < 0.0001), but not on day 14. MIA also generated a transient inflammatory response which peaked on day 1 (P < 0.01) then subsided over the 2-week time course. Joint pain appeared on day 1 and persisted to day 14 (P < 0.0001). By day 14, the saphenous nerve showed signs of demyelination. Early treatment with sivelestat and serpinA1 blocked the proteolytic activity of neutrophil elastase on day 1 (P < 0.001), and caused lasting improvements in joint inflammation, pain, and saphenous nerve damage (P < 0.05). MIA-induced synovitis was reversed by early treatment with GB83 and attenuated in PAR2 knockout mice (P < 0.05). PAR2 knockout mice also showed reduced MIA-induced joint pain (P < 0.0001) and less nerve demyelination (P = 0.81 compared to saline control). Neutrophil elastase and PAR2 contribute significantly to the development of joint inflammation, pain, and peripheral neuropathy associated with experimental OA, suggesting their potential as therapeutic targets.


  • Open Access

    Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice

    by Jason J. McDougall, Milind M. Muley, Holly T. Philpott, Allison Reid, Eugene Krustev

    The endocannabinoid system has been shown to reduce inflammatory flares and pain in rodent models of arthritis. A limitation of endocannabinoids is that they are rapidly denatured by hydrolysing enzymes such as fatty acid amide hydrolase (FAAH) which renders them physiologically inert. Osteoarthritis (OA) is primarily a degenerative joint disease; however, it can incorporate mild inflammation and peripheral neuropathy. The aim of this study was to determine whether early blockade of FAAH bioactivity could reduce OA-associated inflammation and joint neuropathy. The ability of this treatment to prevent end-stage OA pain development was also tested. Physiological saline or sodium monoiodoacetate (MIA; 0.3 mg) was injected into the right knee of male C57Bl/6 mice (20–42 g) and joint inflammation (oedema, blood flow and leukocyte trafficking) was measured over 14 days. Joint inflammation was also measured in a separate cohort of animals treated on day 1 with either saline or the FAAH inhibitor URB597 (0.03–0.3 mg/kg topical onto the knee joint). In other experiments, von Frey hair tactile sensitivity was determined on days 1 and 14 in MIA-injected mice treated prophylactically with URB597 (0.3 mg/kg s.c. over the knee joint on days 0–3). Saphenous nerve myelination was also assessed in these animals on day 14 by G-ratio analysis. Intra-articular injection of MIA caused an increase in joint oedema (P < 0.0001), blood flow (P < 0.05), leukocyte rolling (P < 0.05) and adherence (P < 0.001) on day 1 after treatment which subsequently resolved over later time points. This acute inflammatory response was ameliorated by local URB597 treatment. Prophylactic local administration of URB597 prevented MIA-induced saphenous nerve demyelination, and chronic joint pain was also attenuated. These data indicate that local inhibition of FAAH in MIA-injected knees can reduce acute inflammatory changes associated with the model. Prophylactic treatment of OA mice with the endocannabinoid hydrolysis inhibitor URB597 was also shown to be neuroprotective and prevented the development of joint pain at later time points.


  • Mechanisms and Mediators That Drive Arthritis Pain

    by Eugene Krustev, Danielle Rioux, Jason J. McDougall

    There are over 100 different types of arthritis and each can differ greatly in their aetiology and pathophysiology; however, one characteristic that is common to all arthritic conditions is joint pain. Musculoskeletal pain is the leading cause of disability in the world, and the number one reason arthritis patients visit their primary care physician. Despite the prevalence and burden of arthritis pain, current analgesics lack sufficient efficacy and are plagued by multiple adverse side effects. In this review, we outline the current landscape of research concerning joint pain, drawing from both preclinical and clinical studies. Specifically, this review is a discussion of the different neurophysiological processes that occur during joint disease and how inflammatory and neuropathic aspects contribute to the development of arthritis pain.


  • Faculty Opinions recommendation of Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis.

    by Jason McDougall, Eugene Krustev

    Cannabis has been used for millennia for its health and recreational merits; however, the 'high' produced by cannabis consumption is an unwanted side effect for medicinal cannabis users {1}. Therefore, researchers have begun to focus on how to harness the beneficial effects of cannabinoids without exposing the patient to unwanted psychotropic effects. Two cannabinoid receptors (CBs) have been implicated in the majority of cannabis' effects. CB1 is primarily located on neural tissue and is responsible for the psychotropic effects of cannabis {2}. Conversely, CB2 activation does not affect cognitive function, as it is primarily expressed on peripheral tissues {3}. In joints, CB2 receptors are expressed on synovial tissue and nerves {4}, where their activation includes, but is not limited to, an ability to reduce pain {4}, attenuate synovial inflammation {5}, and reduce bone resorption {6}. The aim of the study by Gui et al. was to investigate if a potent and selective CB2 agonist, HU308, could decrease disease severity in a mouse model of rheumatoid arthritis. This study utilized the collagen induced arthritis model, and assessed inflammation, as well as joint destruction, with or without HU308 treatment (0.3 or 1.0mg/kg; i.p.; once a day for 7 days). High dose HU308 (1.0mg/kg), but not low dose (0.3mg/kg), significantly reduced clinical arthritis scores when compared to vehicle. Furthermore, upon histological assessment, high dose HU308 reduced inflammatory cell infiltration into the synovium and pannus formation. When cartilage and bone damage was assessed, HU308 (1.0mg/kg) attenuated demineralization, joint space narrowing and erosion. In addition to its effectiveness in the joint, HU308 (1.0mg/kg) significantly decreased serum levels of type II collagen antibodies, which are essential for arthritic autoimmunity in this model. Lastly, in vitro, HU308 (1-10μM) significantly decreased interleukin-6 and tumor necrosis factor-α production from lipopolysaccharide-stimulated macrophages, indicating that CB2 receptor agonism can reduce the production of pro-inflammatory mediators. One limitation of this study was that behavioural pain responses were not measured. CB2 agonists are capable of sensitizing arthritic joint afferents {4}; therefore, the protective effects of CB2 activation may be offset by adverse pro-nociceptive effects. Future studies should identify the effects of HU308 on arthritic pain. These results provide evidence that HU308, a CB2 specific agonist, can protect the joint from the effects of inflammation. By specifically targeting CB2, it may be possible to tap into the beneficial effects of the cannabinoid system without unwanted psychotropic effects.

  • Open Access

    Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints

    by Eugene Krustev, Allison Reid, Jason J McDougall

    Introduction: During the progression of rheumatoid arthritis (RA), there are frequent but intermittent flares in which the joint becomes acutely inflamed and painful. Although a number of drug therapies are currently used to treat RA, their effectiveness is variable and side effects are common. Endocannabinoids have the potential to ameliorate joint pain and inflammation, but these beneficial effects are limited by their rapid degradation. One enzyme responsible for endocannabinoid breakdown is fatty acid amide hydrolase (FAAH). The present study examined whether URB597, a potent and selective FAAH inhibitor, could alter inflammation and pain in a mouse model of acute synovitis.Methods: Acute joint inflammation was induced in male C57BL/6 mice by intra-articular injection of 2% kaolin/2% carrageenan. After 24 hr, articular leukocyte kinetics and blood flow were used as measures of inflammation, while hindlimb weight bearing and von Frey hair algesiometry were used as measures of joint pain. The effects of local URB597 administration were then determined in the presence or absence of either the cannabinoid (CB)1 receptor antagonist AM251, or the CB2 receptor antagonist AM630.Results: URB597 decreased leukocyte rolling and adhesion, as well as inflammation-induced hyperaemia. However, these effects were only apparent at low doses and the effects of URB597 were absent at higher doses. In addition to the anti-inflammatory effects of URB597, fatty acid amide hydrolase (FAAH) inhibition improved both hindlimb weight bearing and von Frey hair withdrawal thresholds. The anti-inflammatory effects of URB597 on leukocyte rolling and vascular perfusion were blocked by both CB1 and CB2 antagonism, while the effect on leukocyte adherence was independent of cannabinoid receptor activation. The analgesic effects of URB597 were CB1 mediated.Conclusions: These results suggest that the endocannabinoid system of the joint can be harnessed to decrease acute inflammatory reactions and the concomitant pain associated with these episodes.


  • Faculty Opinions recommendation of Protective effects of C-type natriuretic peptide on linear growth and articular cartilage integrity in an inflammatory arthritis mouse model.

    by Jason McDougall, Eugene Krustev

    Joint inflammation, as a result of juvenile idiopathic arthritis (JIA), not only causes immense pain for the children that suffer from this disease, but also hinders growth and skeletal development {1}. C-type natriuretic peptide (CNP) is a protein that plays a major role in normal skeletal development in humans. Genetic mutations that result in the overexpression of CNP have been linked to skeletal overgrowth {2}, while underexpression of CNP is associated with short stature {3}. The aim of this study was to investigate the effects of chondrocyte-CNP overexpression in mice with experimental autoimmune arthritis (K/BXN TCR). CNP overexpression in K/BXN TCR mice reduced disease progression, prevented growth delay, and inhibited the cartilage damage that is normally observed in this model of autoimmune arthritis. Furthermore, in vitro, chondrocytes overexpressing CNP had increased levels of pro-chondrogenic proteins and were resistant to the damaging effects of inflammatory cytokines. This latter effect may be due in part to the effects of CNP on the chondrocyte transcription factor Sox9, whose expression is reduced by inflammatory cytokines, but rescued by CNP overexpression. These results suggest that promoting CNP expression could protect chondrocytes from the damaging effects of joint inflammation. Furthermore, while immunomodulatory effect of CNP cannot be ruled out completely, it would appear that CNP exerts its effects by directly modulating chondrocyte activity. This is an extremely interesting finding, as it suggests that CNP could prevent disease progression without the side effects associated with immunosuppression. Further research should focus on finding drugs that can directly induce CNP expression and the effects these drugs have on the structural changes observed in autoimmune arthritis.